First Time Loading...

Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 47.99 USD 1.89% Market Closed
Updated: May 21, 2024

Janux Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Janux Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Janux Therapeutics Inc
NASDAQ:JANX
Operating Income
-$73m
CAGR 3-Years
-147%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$7.1B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
12%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
17%

See Also

What is Janux Therapeutics Inc's Operating Income?
Operating Income
-73m USD

Based on the financial report for Dec 31, 2023, Janux Therapeutics Inc's Operating Income amounts to -73m USD.

What is Janux Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-147%

Over the last year, the Operating Income growth was -9%. The average annual Operating Income growth rates for Janux Therapeutics Inc have been -147% over the past three years .